全球唯一！康方生物三抗获批临床

药渡03-09

3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体，旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息，这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2618622203?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-09 18:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2618622203","market":"hk","top_or_hot":-1,"title":"全球唯一！康方生物三抗获批临床","media":"药渡","content":"<div>\n<p>3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体，旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息，这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>全球唯一！康方生物三抗获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n全球唯一！康方生物三抗获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 18:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b><strong>药渡</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体，旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息，这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348827113.USD","symbol_name":"ALLIANZ RCM CHINA \"AT\" ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b","article_id":"2618622203","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309213331a45bcdb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618622203","pubTimestamp":1773050964,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。作为国内抗体药物研发的领军企业之一，康方生物已建立起丰富的产品管线。AK150的临床获批，不仅是康方生物技术平台能力的体现，也标志着国产创新药在多功能抗体领域正加速追赶全球前沿。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","09926":"康方生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","BK1161":"生物科技","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","BK1574":"生物医药B类股","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC"},"translate_title":"The only one in the world! Kangfang Biological's triple antibody was approved for clinical use","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1.5},"content_text":"3月9日，CDE官网显示，康方生物自主研发的注射用AK150正式获批临床，适应症为晚期实体瘤。值得注意的是，AK150是康方生物首款获批临床的三特异性抗体产品，标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体，旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息，这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R的在研三抗产品。巨噬细胞在肿瘤免疫微环境中扮演着“双面角色”，既可抑制肿瘤生长，也可能被肿瘤“策反”成为帮凶。AK150通过同时阻断三条信号通路，有望重编程肿瘤相关巨噬细胞，恢复其抗肿瘤活性，为晚期实体瘤患者带来新的治疗希望。作为国内抗体药物研发的领军企业之一，康方生物已建立起丰富的产品管线。截至目前，公司已有7款产品成功进入市场，包括：5款单抗：覆盖肿瘤、自身免疫等疾病领域（包括2014年授权给科伦的塔戈利单抗）2款双抗：卡度尼利（PD-1/CTLA-4双抗）、依沃西（PD-1/VEGF双抗）其中，卡度尼利和依沃西作为公司双抗平台的代表产品，已在多个适应症中展现出优异的临床价值，奠定了康方在双抗领域的领先地位。从单抗到双抗，再到如今的三抗，抗体药物的复杂性和精准度不断提升。AK150的临床获批，不仅是康方生物技术平台能力的体现，也标志着国产创新药在多功能抗体领域正加速追赶全球前沿。随着AK150进入临床阶段，康方生物将在实体瘤免疫治疗领域迎来新的变量。未来，这款“三抗新星”能否在疗效与安全性上带来惊喜，值得持续关注。*声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618622203","isCrawlerRequest":true}